Why Rare Disease Launches Require a Different Commercialization Strategy
Why rare disease launches require a different commercialization strategy—from patient finding and KOL engagement to market access, evidence generation, treatment infrastructure and patient support.
Why Rare Disease Launches Are Different
Launching a pharmaceutical product is rarely straightforward. For rare disease therapies, however, the commercial model can be fundamentally different.
A conventional launch may focus on identifying a large addressable patient population, building physician awareness, securing payer coverage, and scaling sales. A rare disease commercialization strategy must often solve a more fundamental problem first: finding the patients who have the disease, confirming their diagnosis, and connecting them with the appropriate treatment pathway.
This challenge is becoming more important as the rare disease pipeline expands. In 2025, the U.S. FDA reported that 23 of 46 novel drugs approved by CDER—50%—received orphan drug designation. FDA also notes that approximately 25–30 million Americans live with rare diseases, spanning roughly 10,000 rare diseases and conditions.
The result is a major strategic shift: rare disease commercialization is increasingly about patient finding, ecosystem activation, evidence generation, and access—not simply product promotion.
01 · Patient Intelligence
1. Patient Identification Comes Before Commercial Scale
One of the defining characteristics of rare disease drug commercialization is the difficulty of identifying the addressable patient population.
Patients can remain undiagnosed for years, receive incorrect diagnoses, or move between multiple specialists before reaching an appropriate treatment center. Small populations can also make conventional market-sizing approaches less reliable.
IQVIA's September 2026 analysis highlights patient finding as a strategic issue affecting prevalence estimation, clinical-trial recruitment, evidence generation, launch readiness and market sizing.
Therefore, a rare disease launch strategy should map the patient journey before determining sales-force deployment.
This can include:
- Diagnostic pathways and referral patterns
- Disease awareness gaps
- Centers of excellence
- Genetic testing pathways
- Specialist networks
- Patient advocacy organizations
- Undiagnosed and misdiagnosed populations
- Treatment eligibility criteria
- Geographic concentration of patients
Commercial implication: the true opportunity is not simply the diagnosed population. It is the population that can realistically be identified, diagnosed, treated, and supported.
02 · KOL Intelligence
2. KOL Strategy Becomes an Ecosystem Strategy
Traditional pharmaceutical launches often prioritize a defined group of high-prescribing physicians.
Rare disease launches require a broader KOL strategy.
A small number of specialists may influence diagnosis, clinical guidelines, testing practices, referral behavior, treatment initiation, and peer education. At the same time, patient organizations, genetic counselors, specialist nurses, diagnostic laboratories and centers of excellence can influence the patient journey.
Rare disease KOL mapping
This makes rare disease KOL mapping particularly valuable.
Instead of asking only:
“Who prescribes the most?”
commercial teams should ask:
“Who influences diagnosis, referral, treatment decisions, evidence generation and standards of care?”
Advanced KOL intelligence can therefore combine:
- Publication influence
- Clinical-trial involvement
- Guideline participation
- Referral networks
- Conference activity
- Digital influence
- Institutional affiliations
- Patient-community engagement
- Emerging scientific expertise
This creates a stakeholder map rather than a conventional prescriber list.
03 · Market Access
3. Market Access Must Be Designed Earlier
Another major difference is the complexity of rare disease market access.
Many rare disease therapies involve high development costs, limited patient populations, specialized administration, or advanced modalities such as gene and cell therapies. Consequently, the payer conversation can involve more than price.
Evidence requirements may include:
- Long-term outcomes
- Disease progression
- Patient-reported outcomes
- Real-world evidence
- Quality-of-life impact
- Healthcare-resource utilization
- Durability of treatment benefit
- Budget impact
The market-access strategy therefore needs to begin well before launch.
For example, Vertex's CASGEVY commercialization illustrates the importance of reimbursement infrastructure. By the end of 2025, Vertex reported reimbursed access for CASGEVY in multiple countries and approximately 90% of U.S. patients having reimbursed access.
Regulatory approval creates the possibility of commercialization; reimbursement and treatment infrastructure create actual access.
04 · Market Shaping
4. Rare Disease Launches Often Require Market Shaping
In established therapeutic categories, pharmaceutical companies may enter a market where physicians already understand the disease and treatment pathway.
Rare diseases can be different.
Commercial teams may need to help build awareness of:
- Disease symptoms
- Diagnostic criteria
- Appropriate testing
- Referral pathways
- Treatment eligibility
- Centers capable of administering therapy
- Patient support resources
IQVIA's 2026 rare-disease framework identifies patient and health-system opportunity, value and evidence, and market shaping and stakeholder strategy as interconnected capabilities for rare disease commercialization.
This means the rare disease go-to-market strategy can involve market development alongside product commercialization.
05 · Patient Support
5. Patient Support Can Become Part of the Commercial Model
For complex rare disease therapies, the patient journey does not end with prescription.
Patients may face insurance verification, prior authorization, specialist referrals, treatment-center requirements, travel, administration logistics and ongoing monitoring.
Sarepta's SareptAssist program, for example, provides support around insurance benefits, financial assistance, treatment logistics and ongoing education. Its case managers work with patients and families navigating treatment access.
For rare disease companies, patient support therefore needs to be considered as part of the commercialization model, while maintaining appropriate legal, ethical, privacy and promotional boundaries.
06 · Evidence Strategy
6. Launch Planning Must Account for Evidence Uncertainty
Rare disease development can involve small clinical populations, heterogeneous disease characteristics and limited natural-history data. FDA identifies these as important challenges in rare disease clinical development.
That creates commercial implications.
A launch plan should anticipate questions such as:
- What evidence will physicians require?
- What outcomes matter to payers?
- Which endpoints demonstrate meaningful patient benefit?
- What real-world evidence will be required after launch?
- How will long-term outcomes influence reimbursement?
The commercial organization, medical affairs team, market access function and HEOR teams therefore need to operate from a shared evidence strategy.
Industry Examples
What Leading Companies Are Doing Differently
Novartis
Novartis has highlighted healthcare-system readiness and global access as strategic priorities. Its current sustainability targets include global access strategies for new medicines and healthcare-system readiness roadmaps covering areas including rare renal diseases and Huntington's disease.
For Zolgensma, Novartis also established a global managed-access program that treated nearly 300 children with SMA across 40 countries while longer-term access pathways were developed.
Vertex
Vertex has focused on reimbursement agreements and treatment access for CASGEVY, illustrating the importance of aligning regulatory approval with healthcare-system readiness.
Sarepta
Sarepta demonstrates another dimension: rare disease commercialization requires operational infrastructure around treatment delivery, patient support, market access and community engagement.
Together, these examples point toward a broader model: rare disease commercialization is an ecosystem orchestration exercise.
Framework
A Practical Rare Disease Commercialization Framework
A pharmaceutical company preparing for a rare disease launch can structure its strategy around six connected workstreams.
| Workstream | Key commercial question |
|---|---|
| Patient intelligence | Where are the diagnosed and undiagnosed patients? |
| KOL intelligence | Who influences diagnosis and treatment? |
| Market access | What evidence and reimbursement pathway are required? |
| Market shaping | What must change in disease awareness or diagnosis? |
| Patient support | What barriers exist between prescription and treatment? |
| Evidence strategy | What evidence is required throughout the product lifecycle? |
This integrated approach can provide a stronger foundation for rare disease launch planning than a conventional sales-and-marketing model.
Industry Insight
Industry Insight: The Future of Rare Disease Commercialization
The next generation of rare disease launches is likely to become increasingly data-driven.
Patient-level analytics, real-world data, genomic information, referral-network analysis, AI-assisted patient finding and advanced KOL intelligence can help companies identify opportunities that traditional market research may miss.
The strategic question is consequently shifting from:
“How large is the market?”
to:
“Where are the patients, how do they move through the healthcare system, who influences their treatment, and what prevents them from receiving therapy?”
That shift will make rare disease market intelligence, patient journey analysis, KOL mapping and market-access intelligence increasingly important components of pharmaceutical commercial planning.
Frequently Asked Questions
Frequently Asked Questions
Conclusion
Why Rare Disease Launches Require a Different Commercialization Strategy
A rare disease launch cannot be treated simply as a smaller version of a conventional pharmaceutical launch.
The rare disease commercialization strategy must connect patient identification, diagnosis, KOL influence, market access, evidence generation, healthcare-system readiness and patient support.
As rare disease pipelines continue to expand—with half of CDER's novel drug approvals receiving orphan designation in 2025—the competitive advantage will increasingly come from understanding the entire disease ecosystem, not just the product.
For pharmaceutical companies, the most effective commercialization models will be those that identify patients earlier, understand stakeholder influence more precisely, anticipate access barriers and use data to continuously refine launch decisions.
.webp)